analyses, and is in the process of determining final working  capital adjustments. Therefore, a preliminary allocation of the  purchase price to the acquired assets, liabilities, and goodwill  is presented in the table below. The reported net earnings attributable to the Company were  used when computing basic and diluted earnings per share for  all years presented. A reconciliation of the shares used in the  computation is as follows: For fiscal years 2014, 2013, and 2012, a total of 0.4 million, 0.4  million, and 2.2 million weighted-average outstanding stock  options, respectively, were not included in the computation of  dilutive potential common shares since their inclusion would  have had an antidilutive effect on earnings per share. The liabilities shown above include $15.0 million representing  potential payments owed under a supplier agreement, which  are contingent on future production levels.  Goodwill is calculated as the excess of the purchase price  over the fair value of the net assets recognized. The goodwill  recorded as part of the acquisition primarily reflects the value  of the assembled workforce, manufacturing synergies, and  the potential to expand presence in alternate channels. The  goodwill balance is not expected to be deductible for income  tax purposes. The goodwill and intangible assets have been  allocated to the Specialty Foods and International & Other  reporting segments. On August 11, 2014, the Company acquired CytoSport  Holdings, Inc. (CytoSport) of Benicia, California for a prelim- inary purchase price of $424.3 million in cash. The purchase  price is preliminary pending final working capital and other  purchase accounting adjustments, and was funded by the  Company with cash on hand and by utilizing funds from its  revolving line of credit. The agreement provides for a potential  additional payment of up to $20.0 million subject to meeting  specific financial performance criteria over the next two years.  The Company has recognized $10.3 million related to this  potential payment as of October 26, 2014, based on the current  estimated fair value determined by an independent appraisal. Operating results for this acquisition have been included in  the Company’s Consolidated Statements of Operations from  the date of acquisition and are reflected in the Specialty Foods  reporting segment. The acquisition contributed $73.5 million  of net sales since the date of acquisition. The Company recognized approximately $4.8 million of trans- action costs in fiscal year 2014 related to the acquisition and  the charges were reported in selling, general and administra- tive expense in the Consolidated Statement of Operations. CytoSport is the maker of  Muscle Milk ®  products and is a lead- ing provider of premium protein products in the sports nutri- tion category. CytoSport’s brands align with the Company’s  focus on protein while further diversifying the Company’s  portfolio. The acquisition was accounted for as a business combination  using the acquisition method. The Company has estimated  the acquisition date fair values of the assets acquired and  liabilities assumed, using independent appraisals and other  On November 26, 2013, the Company acquired the China  based  SKIPPY ® peanut butter business from Conopco, Inc.  (doing business as Unilever United States Inc.), of Englewood  Cliffs, N.J. for a final purchase price of $41.9 million in cash.  This acquisition included the Weifang, China manufacturing  facility and all sales in Mainland China. The purchase price  was funded by the Company with cash on hand. 44 Note D Acquisitions Note C Earnings Per Share Data (in thousands) Accounts receivable  $ 37,541 Inventory  62,246 Prepaid and other assets  3,133 Property, plant and equipment  8,119 Intangible assets   183,607 Goodwill   263,829 Current liabilities   (52,298) Long-term liabilities   (25,182) Deferred taxes   (56,667) Purchase price  $424,328 (in thousands)  2014 2013  2012 Basic weighted-average shares outstanding  263,812 264,317  263,466 Dilutive potential common shares  6,404 5,907  5,425 Diluted weighted-average shares outstanding  270,216 270,224  268,891